Alpine Immune Sciences (NASDAQ:ALPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The brokerage presently has a $13.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 15.66% from the company’s current price.
According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “
Separately, ValuEngine upgraded Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $10.83.
Alpine Immune Sciences (NASDAQ:ALPN) opened at $11.24 on Tuesday. The stock has a market capitalization of $155.34 and a price-to-earnings ratio of -1.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 32.38 and a quick ratio of 32.38. Alpine Immune Sciences has a 52 week low of $7.20 and a 52 week high of $14.52.
A hedge fund recently bought a new stake in Alpine Immune Sciences stock. Sowell Financial Services LLC bought a new stake in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned 0.40% of Alpine Immune Sciences as of its most recent SEC filing.
About Alpine Immune Sciences
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.